Pacylex

Pacylex Granted FDA Fast Track Designation for PCLX-001 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Pacylex Granted FDA Fast Track Designation for PCLX-001 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia First in class therapy moves closer to clinical trial of PCLX-001 in Acute Myeloid Leukemia

Read More

Recent News

Pacylex

Pacylex Pharmaceuticals announces progress on early phase clinical trials of PCLX-001 in patients

Read More

Pacylex

Pacylex Announces Orphan Drug Designation Granted to PCLX-001 for the Treatment of Acute Myeloid Leukemia

Read More

Pacylex

Major Grant Awarded to Study PCLX-001 in Acute Myeloid Leukemia Patients

Read More
Follow Pacylex